Status:
COMPLETED
Effects of Body Mass Index on the Hyperemic Response to Regadenoson
Lead Sponsor:
University of Utah
Collaborating Sponsors:
Astellas Pharma Inc
Conditions:
Obesity
Endothelial Dysfunction
Eligibility:
All Genders
18-88 years
Phase:
NA
Brief Summary
We will test the hypothesis that a single dose of Regadenoson will produce equivalent degrees of coronary hyperemia in patients of widely different body size. This will be a prospective, open-label, c...
Detailed Description
Introduction: Regadenoson (Lexiscan) is currently recommended for use as a targeted vasodilator in myocardial perfusion studies and is available as a single, fixed dose for all patients. Here we propo...
Eligibility Criteria
Inclusion
- BMI 20-40 kg/m\^2
- age 18-88
Exclusion
- critically ill patients, patients on ventilators, patients with hypotension, asthmatics, and other patients whose medical care or safety may be compromised from undergoing an MRI examination will be excluded.
- Patients with claustrophobia will also be excluded.
- Also, anyone with contraindications to MRI (pacemaker, ICD, metal implants), pregnant subjects, minors, and prisoners will be excluded from this study.
- If subjects are over 60 or have any suspicion of abnormal kidney function, a blood test to determine GFR will be performed prior to imaging.
- Subjects with GFR \< 30 will be excluded from the study.
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00859833
Start Date
February 1 2009
End Date
July 1 2010
Last Update
May 24 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Utah
Salt Lake City, Utah, United States, 84132